Edgewise Therapeutics, Inc.
A clinical-stage biopharmaceutical company in Boulder, Colorado that makes swallowed pills designed to treat serious muscle diseases. Its drugs tune myosin, the protein that drives muscle contraction, to protect fragile fibers in muscular dystrophies and to ease the stiff, thickened heart muscle of hypertrophic cardiomyopathy. Founded in 2017 by four scientists and drug developers, the company went public on Nasdaq in 2021.
Bought 1.93M
Bought 1.93M
Bought 1.11M
Bought 625.0K
Bought 15.6K
Granted 58.9K · Sold 28.2K
Granted 578.4K · Sold 827.7K
Granted 115.5K · Sold 115.5K
Granted 296.5K · Sold 221.3K
Granted 162.0K · Sold 168.7K
Granted 83.5K · Sold 69.7K
Granted 3.0K · Bought 21.6K
Granted 329.8K · Sold 324.8K
Granted 29.7K · Sold 29.7K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Orbimed Advisors LLC +2 co-filersDirector, 10% owner · 9 transactions | — | 15.25Mas of Apr 2025 | — | 1.93M | — |
| Thompson Peter A.Director, 10% owner · 9 transactions | — | 15.25Mas of Apr 2025 | — | 1.93M | — |
| Novo Holdings A/S10% owner · 3 transactions | — | 6.07Mas of Sep 2022 | — | 1.11M | — |
| Deerfield Management Company, L.P. (Series C) +3 co-filersReporting owner · 4 transactions | — | 3.93Mas of Mar 2021 | — | 625.0K | — |
| Root Jonathan DDirector · 3 transactions | — | 3.49Mas of Feb 2022 | — | 15.6K | — |
| Wellington Biomedical Innovation Master Investors (Cayman) I L.P.10% owner · 1 transaction | — | 681.8Kas of Mar 2021 | — | — | — |
| Koch KevinPresident and CEO, Director · 14 transactions | — | 403.8Kas of Aug 2025 | 58.9K | — | 28.2K |
| Russell Alan JChief Scientific Officer, Director · 62 transactions | — | 123.4K | 578.4K | — | 827.7K |
| Edris BadreddinDirector · 10 transactions | — | 96.8K | 115.5K | — | 115.5K |
| Carruthers R MichaelChief Financial Officer · 19 transactions | — | 86.2Kas of Aug 2025 | 296.5K | — | 221.3K |
| Donovan Joanne M.CMO · 20 transactions | — | 54.4K | 162.0K | — | 168.7K |
| Derakhshan BehradChief Business Officer · 18 transactions | — | 26.1Kas of Aug 2025 | 83.5K | — | 69.7K |
| Fox Jonathan CDirector · 7 transactions | — | 24.5K | 3.0K | 21.6K | — |
| Moore John RGeneral Counsel · 64 transactions | — | 12.3Kas of Aug 2025 | 329.8K | — | 324.8K |
| Semigran MarcChief Development Officer · 3 transactions | — | 6.7Kas of Dec 2024 | 29.7K | — | 29.7K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +3.85M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.